Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study –
Hisao Ogawa, Kunihiko Matsui, Yoshihiko Saito, Seigo Sugiyama, Hideaki Jinnouchi, Masahiro Sugawara, Izuru Masuda, Hisao Mori, Masako Waki, Minoru Yoshiyama, Hirotaka Watada, Hisao Ogawa, Kunihiko Matsui, Yoshihiko Saito, Seigo Sugiyama, Hideaki Jinnouchi, Masahiro Sugawara, Izuru Masuda, Hisao Mori, Masako Waki, Minoru Yoshiyama, Hirotaka Watada
Abstract
Background: Little is known about the differences between standard-dose statins effects on glucose level and lipids in Japanese patients with diabetes mellitus (DM).
Methods and results: The 1,049 patients were randomly assigned to either the rosuvastatin group or atorvastatin group. There were no significant differences between the 2 groups in the effect on non-high-density lipoprotein cholesterol (non-HDL-C) and HbA1c at 12 months. However, physicians tended to switch to more intensive therapy for DM in the atorvastatin group.
Conclusions: Rosuvastatin 5 mg and atorvastatin 10 mg have a similar lowering effect on non-HDL-C, but might be different in terms of adverse effect on glucose levels.
Trial registration: ClinicalTrials.gov NCT01544309.
Source: PubMed